睿知中国医院研究地图
候选清单

天津

天津市胸科医院

Tianjin Chest Hospital

在本站收录的 61 种疾病中,这家医院列在其中 5 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

天津市胸科医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 肺癌Lung cancer39 篇牵头论文
  2. 冠心病Coronary heart disease36 篇牵头论文牵头 2 项开放试验
  3. 先天性心脏病Congenital heart disease4 篇牵头论文
  4. 特发性肺纤维化Idiopathic pulmonary fibrosis3 篇牵头论文
  5. 法布雷病Fabry disease1 篇牵头论文

未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、肝细胞癌、胃癌、胰腺癌、乳腺癌、胶质瘤、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、骨肉瘤、胃肠道间质瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、淋巴瘤、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、脊柱侧弯、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 39 篇,占 0.2%。

牵头论文
39
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
9
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 5520222023: 6620232024: 5520242025: 16162025

天津有 7 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    分期
    III期
    开始
    2026-04
    发布
    登记号
    NCT07416474

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 66 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、桂林、武汉、江门、沈阳、洛阳、济南、深圳、温州、烟台、珠海、石家庄、福州、苏州、襄阳、郑州、重庆、银川、长春、长沙、青岛

  2. 正在招募
    A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
    分期
    II期
    开始
    2026-07
    发布
    登记号
    NCT07586202

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、北京、天津、广州、成都、济南

  3. 正在招募
    A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
    分期
    II期
    开始
    2025-06
    发布
    登记号
    NCT06962865

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心临沂、北京、哈尔滨、天津、太原、广州、成都、昆明、杭州、桂林、武汉、济南、温州、烟台、石家庄、福州、襄阳、郑州、重庆、长春、长沙

  4. 正在招募
    Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
    分期
    III期
    开始
    2025-08
    发布
    登记号
    NCT07154706

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、南通、天津、广州、成都、杭州、武汉、济南、西安、郑州

  5. 正在招募
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    分期
    III期
    开始
    2025-12
    发布
    登记号
    NCT07182682

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 47 家列出的医院为研究中心上海、北京、南京、南宁、台州、合肥、哈尔滨、天津、太原、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、福州、西安、郑州、长春、长沙

  6. 正在招募
    Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
    分期
    III期
    开始
    2025-12
    发布
    登记号
    NCT07185997

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、临沂、佛山、北京、南京、南宁、南昌、南通、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、新乡、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、潍坊、石家庄、福州、郑州、重庆、长沙、青岛

  7. 正在招募
    A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
    分期
    II期
    开始
    2023-06
    发布
    登记号
    NCT05913089

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、天津、太原、潍坊、福州

  8. 即将招募
    A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
    分期
    III期
    开始
    2023-11
    发布
    登记号
    NCT05990127

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、乌鲁木齐、北京、南昌、合肥、哈尔滨、天津、太原、广州、徐州、成都、新乡、昆明、杭州、武汉、沈阳、洛阳、济南、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、银川、长春、长沙、青岛

  9. 邀请入组
    Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
    分期
    III期
    开始
    2021-08
    发布
    登记号
    NCT04762459

    年龄 18 岁 至 130 岁(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、天津、太原、宁波、广州、成都、昆明、杭州、武汉、沈阳、深圳、温州、潍坊、石家庄、苏州、西安、郑州、重庆、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科影像/核医学科放疗科

这些论文过半是实验室或动物研究。

医院名称从作者地址自动识别,尚未人工核对。

牵头的论文39
  1. Enhanced pulmonary nodule detection with U-Net, YOLOv8, and swin transformer.2025BMC medical imaging免费全文
  2. Identifying diagnostic markers and establishing prognostic model for lung cancer based on lung cancer-derived exosomal genes.2025Cancer biomarkers : section A of Disease markers免费全文
  3. A radiomics-based machine learning model and SHAP for predicting spread through air spaces and its prognostic implications in stage I lung adenocarcinoma: a multicenter cohort study.2025Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  4. Spatial transcriptomic analysis across histological subtypes reveals molecular heterogeneity and prognostic markers in early-stage lung adenocarcinoma.2025Clinical and translational medicine免费全文
  5. Kaempferitrin Regulates the Proliferation, Metastasis, and Immune Escape of Nonsmall Cell Lung Cancer by Inhibiting the Akt/NF-κB Pathway.2025Drug development research
  6. Guanylate-binding proteins score and a CBFA2T3-included risk model define immune microenvironment and chemosensitivity in lung adenocarcinoma.2025European journal of medical research免费全文
  7. Integrative modeling of malignant epithelial programs in EGFR-mutant LUAD via single-cell transcriptomics and multi-algorithm machine learning.2025Frontiers in immunology免费全文
  8. Single-cell transcriptomic profiling reveals the heterogeneity of epithelial cells in lung adenocarcinoma lymph node metastasis and develops a prognostic signature.2025Frontiers in immunology免费全文
  9. Development of a machine learning-derived dendritic cell signature for prognostic stratification in lung adenocarcinoma.2025Frontiers in immunology免费全文
  10. Falcarindiol Suppresses Malignant Progression and Induces Ferroptosis in Non-Small Cell Lung Cancer by Regulating JAK/STAT3 Axis.2025Journal of biochemical and molecular toxicology
  11. Integrative single-cell and machine learning approach to characterize immunogenic cell death and tumor microenvironment in LUAD.2025Journal of translational medicine免费全文
  12. A Machine Learning-Derived Taurine Metabolism Signature Predicts Prognosis and Immune Landscape in Lung Adenocarcinoma via Integrative Single-Cell Analysis.2025Mediators of inflammation免费全文
  13. Sennoside A represses the malignant phenotype and tumor immune microenvironment of non-small cell lung cancer cells by inhibiting the TRAF6/NF-κB pathway.2025Naunyn-Schmiedeberg's archives of pharmacology
  14. A nicotinamide metabolism-related gene signature for predicting immunotherapy response and prognosis in lung adenocarcinoma patients.2025PeerJ免费全文
  15. Druggable genome-wide Mendelian randomization integrating GWAS and eQTL/pQTL data identifies targets for lung squamous cell carcinoma.2025Scientific reports免费全文
  16. Single-Cell and Spatial Transcriptomics-Based Research Reveals Association Between M2a Macrophages and Tumor Spread through Air Spaces in Lung Adenocarcinoma.2025The American journal of pathology
  17. Preoperative assessment of tertiary lymphoid structures in stage I lung adenocarcinoma using CT radiomics: a multicenter retrospective cohort study.2024Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  18. Macrophage heterogeneity and oncogenic mechanisms in lung adenocarcinoma: insights from scRNA-seq analysis and predictive modeling.2024Frontiers in immunology免费全文
  19. Integrative single-cell analysis of LUAD: elucidating immune cell dynamics and prognostic modeling based on exhausted CD8+ T cells.2024Frontiers in immunology免费全文
  20. Sinensetin inhibits the movement ability and tumor immune microenvironment of non-small cell lung cancer through the inactivation of AKT/β-catenin axis.2024Journal of biochemical and molecular toxicology
  21. CRTAC1 identified as a promising diagnosis and prognostic biomarker in lung adenocarcinoma.2024Scientific reports免费全文
  22. CircPIM3 regulates taxol resistance in non-small cell lung cancer via miR-338-3p/TNFAIP8 axis.2023Anti-cancer drugs
  23. A pretreatment prediction model of grade 3 tumors classed by the IASLC grading system in lung adenocarcinoma.2023BMC pulmonary medicine免费全文
  24. Screening of potential microbial markers for lung cancer using metagenomic sequencing.2023Cancer medicine免费全文
  25. Real-world surgical treatment patterns and clinical outcomes in patients with stages IA-IIIA non-small cell lung cancer: a retrospective multicentric observational study involving 11,958 patients.2023Journal of cancer research and clinical oncology免费全文
  26. Mediastinal cavernous hemangioma with concurrent primary lung adenocarcinoma.2023Pulmonology
  27. SETD1A-mediated H3K4me3 methylation upregulates lncRNA HOXC-AS3 and the binding of HOXC-AS3 to EP300 and increases EP300 stability to suppress the ferroptosis of NSCLC cells.2023Thoracic cancer免费全文
  28. Impact of preoperative biopsy on tumor spread through air spaces in stage I non-small cell lung cancer: a propensity score-matched study.2022BMC pulmonary medicine免费全文
  29. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.2022Cancer control : journal of the Moffitt Cancer Center免费全文
  30. Pretreatment prediction of tumour spread through air spaces in clinical stage I non-small-cell lung cancer.2022European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery免费全文
  31. ZNF143 Expression is Associated with COPD and Tumor Microenvironment in Non-Small Cell Lung Cancer.2022International journal of chronic obstructive pulmonary disease免费全文
  32. Identification of Recurrent Insertions and Deletions in Exon 18 and 19 of Human Epidermal Growth Factor Receptor 2 as Potential Drivers in Non-Small-Cell Lung Cancer and Other Cancer Types.2022JCO precision oncology免费全文
  33. Multi-line treatment with tyrosine kinase inhibitors enabled in 4-year survival for patient with stage IV lung adenocarcinoma: a case report.2021Annals of palliative medicine
  34. Investigation of differentially expressed gene profile for cisplatin-treated lung cancer patients.2021Anti-cancer drugs
  35. The risk and prognostic factors for brain metastases in esophageal cancer patients: an analysis of the SEER database.2021BMC cancer免费全文
  36. Perioperative outcomes of combined heart surgery and lung tumor resection: a systematic review and meta-analysis.2021Journal of cardiothoracic surgery免费全文
  37. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.2021Journal of clinical laboratory analysis免费全文
  38. Glutathione S‑transferase ω 1 promotes the proliferation, migration and invasion, and inhibits the apoptosis of non‑small cell lung cancer cells, via the JAK/STAT3 signaling pathway.2021Molecular medicine reports免费全文
  39. Elevated expression of ASF1B correlates with poor prognosis in human lung adenocarcinoma.2021Personalized medicine
中文论文(未计入)1
  1. [Analysis of Influencing Factors of Complications for CT-guided 
Percutaneous Lung Biopsy].2024Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)26
  1. Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD状态不明NCT05578222牵头方II期2022-10 启动
  2. A Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung Cancer已完成NCT03429192牵头方2017-12 启动
  3. RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)正在招募NCT07416474研究中心III期2026-04 启动
  4. A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC正在招募NCT07586202研究中心II期2026-07 启动
  5. Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)正在招募NCT07154706研究中心III期2025-08 启动
  6. A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC正在招募NCT06962865研究中心II期2025-06 启动
  7. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations正在招募NCT07185997研究中心III期2025-12 启动
  8. A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery正在招募NCT07182682研究中心III期2025-12 启动
  9. A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer即将招募NCT05990127研究中心III期2023-11 启动
  10. A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer正在招募NCT05913089研究中心II期2023-06 启动
  11. Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection邀请入组NCT04762459研究中心III期2021-08 启动
  12. Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)进行中,不再招募NCT07162883研究中心III期2025-11 启动
  13. Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)进行中,不再招募NCT06577792研究中心不分期2023-08 启动
  14. A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)进行中,不再招募NCT05722015研究中心III期2023-02 启动
  15. Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.状态不明NCT05922345研究中心III期2023-06 启动
  16. Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium已完成NCT05273827研究中心2022-03 启动
  17. A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)状态不明NCT04964479研究中心III期2021-08 启动
  18. A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China已完成NCT04830826研究中心2020-07 启动
  19. A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer状态不明NCT04439890研究中心III期2019-08 启动
  20. Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC Patients已完成NCT03613467研究中心2018-07 启动
  21. Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection已终止NCT03479294研究中心2018-03 启动
  22. A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung Cancer已完成NCT03451526研究中心2017-12 启动
  23. A Study to Evaluate Effectiveness and Safety of Surgeries in Elderly NSCLC Patients已完成NCT03429673研究中心2017-12 启动
  24. A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases状态不明NCT03427541研究中心2017-12 启动
  25. A Study to Evaluate Clinical Characteristics of Lung Cancer in Patients With Surgeries and Adjuvant Therapies已完成NCT03421093研究中心2017-12 启动
  26. A Study to Evaluate Effectiveness of Sublobar Dissection in Patients With Non-small Cell Lung Cancer已完成NCT03427567研究中心2017-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

冠心病

Coronary heart disease

2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 36 篇,占 0.7%。

牵头论文
36
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 9920222023: 8820232024: 9920242025: 332025

天津有 9 家医院列在冠心病下全国有 231 家医院列在冠心病下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    TTE Improves Clinical Management of Stable Chest Pain
    分期
    未注明
    开始
    2025-01
    发布
    登记号
    NCT07063147

    年龄 18 岁 至 未注明(登记的条件)

    牵头:天津市胸科医院天津

  2. 正在招募
    CCTA Improves Clinical Management of Stable Chest Pain
    分期
    未注明
    开始
    2016-01
    发布
    登记号
    NCT04691037

    年龄 18 岁 至 未注明(登记的条件)

    牵头:天津市胸科医院;另有 2 家列出的医院为研究中心北京、天津

  3. 正在招募
    Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
    分期
    IV期
    开始
    2025-11
    发布
    登记号
    NCT07110415

    年龄 40 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、兰州、北京、南京、南宁、哈尔滨、大庆、大连、天津、宁波、广州、张家口、成都、杭州、汕头、沈阳、济南、深圳、湖州、烟台、珠海、石家庄、西安、贵阳、重庆、银川、长春、青岛

  4. 即将招募
    Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
    分期
    不分期
    开始
    2021-09
    发布
    登记号
    NCT04995159

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 67 家列出的医院为研究中心上海、中山、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、天津、太原、广州、徐州、昆明、杭州、武汉、汕头、洛阳、济南、海口、淄博、淮安、湛江、烟台、珠海、石家庄、蚌埠、西安、贵阳、郑州、重庆、银川、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科影像/核医学科

医院名称从作者地址自动识别,尚未人工核对。

牵头的论文36
  1. Relationship between coronary artery calcification and plaque vulnerability, a qualitative and quantitative optical coherence tomography study.2025International journal of cardiology
  2. Electrocardiographic and clinical predictors for in-hospital mortality in patients with acute myocardial infarction caused by left main coronary artery occlusion.2025Medicine免费全文
  3. A sensing strategy based on novel pyrene-functionalized MOFs for sVCAM-1 detection and prognostic assessment in coronary heart disease.2025Talanta
  4. Interventional treatment of non-spontaneously healed spontaneous coronary artery dissection: a case report.2024BMC cardiovascular disorders免费全文
  5. The relative and combined ability of stress hyperglycemia ratio and N-terminal pro-B-type natriuretic peptide to predict all-cause mortality in diabetic patients with multivessel coronary artery disease.2024Cardiovascular diabetology免费全文
  6. Triglyceride-glucose Index as a Valuable Marker to Predict Severity of Coronary Artery Disease: A Retrospective Cohort Study.2024Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis免费全文
  7. The Effect of Angiotensin Receptor Blockers on In-Stent Restenosis After Stent Implantation: A Meta-Analysis.2024Heart, lung & circulation
  8. Differential Expression of mRNA in Peripheral Blood Mononuclear Cells May Predict Postoperative Atrial Fibrillation in Coronary Artery Bypass Surgery Patients.2024Journal of cardiovascular translational research免费全文
  9. Association of the PCSK6 rs1531817(C/A) polymorphism with the prognosis and coronary stenosis in premature myocardial infarction patients: a prospective cohort study.2024Lipids in health and disease免费全文
  10. Proprotein convertase subtilisin/kexin 9 inhibitor downregulates microRNA-130a-3p expression in hepatocytes to alleviates atherosclerosis progression.2024Naunyn-Schmiedeberg's archives of pharmacology
  11. Monocyte to high-density lipoprotein cholesterol ratio predicts restenosis of drug-eluting stents in patients with unstable angina pectoris.2024Scientific reports免费全文
  12. Comparison of clinical effects of coronary artery bypass grafting between left anterior small thoracotomy approach and lower-end sternal splitting approach.2024The Journal of international medical research免费全文
  13. Diagnostic Performance of Machine Learning-Derived Radiomics Signature of Pericoronary Adipose Tissue in Coronary Computed Tomography Angiography for Coronary Artery In-Stent Restenosis.2023Academic radiology
  14. Lipoprotein Subfractions as Markers for Predicting the Presence and Severity of Coronary Artery Disease in Patients Undergoing Coronary Angiography.2023Angiology
  15. Electrocardiographic changes in acute myocardial infarction with acute occlusion of all triple coronary arteries.2023Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc免费全文
  16. Comparison of two diagnostic strategies for patients with stable chest pain suggestive of chronic coronary syndrome: rationale and design of the double-blind, pragmatic, randomized and controlled OPERATE Trial.2023BMC cardiovascular disorders免费全文
  17. Comparison of risk assessment strategies incorporating coronary artery calcium score with estimation of pretest probability to defer cardiovascular testing in patients with stable chest pain.2023BMC cardiovascular disorders免费全文
  18. Characterization of lncRNA-associated ceRNA network to uncover novel potential biomarkers in coronary artery disease.2023Medicine免费全文
  19. Kinesiophobia and self-management behaviour related to physical activity in Chinese patients with coronary heart disease: The mediating role of self-efficacy.2023Nursing open免费全文
  20. A five-parameter score for predicting saphenous vein graft degenerative and/or occlusive disease in recurring ischemic symptoms after one year post coronary artery bypass grafting.2023Perfusion
  21. The Preventive Effect of Alprostadil on the Contrast-Induced Nephropathy of Coronary Heart Disease Treated by Percutaneous Coronary Intervention in Moderate and High-Risk Population Stratified by Mehran Score.2022AngiologyRCT
  22. Perioperative coronary artery spasm after off-pump coronary artery bypass grafting in the non-manipulated coronary artery.2022BMC cardiovascular disorders免费全文
  23. Correlation of triglyceride-glucose index and dyslipidaemia with premature coronary heart diseases and multivessel disease: a cross-sectional study in Tianjin, China.2022BMJ open免费全文
  24. Impact of persistent subclinical hypothyroidism on clinical outcomes in non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention.2022Clinical endocrinology
  25. Coronary calcification improves the estimation for clinical likelihood of obstructive coronary artery disease and avoids unnecessary testing in patients with borderline pretest probability.2022European journal of preventive cardiology
  26. Comparison of Different Investigation Strategies to Defer Cardiac Testing in Patients With Stable Chest Pain.2022JACC. Cardiovascular imaging
  27. Correlation between platelet-derived growth factor-B gene polymorphism and coronary heart disease.2022Journal of clinical laboratory analysis免费全文
  28. Validation and Comparison of PROMISE and CONFIRM Model to Predict High-Risk Coronary Artery Disease in Symptomatic and Diabetes Mellitus Patients.2022Reviews in cardiovascular medicine
  29. Comparison of NICE and ESC strategy for risk assessment in women with stable chest pain: a coronary computed tomography angiography study.2022Reviews in cardiovascular medicine
  30. Inflammatory Indicators and Hematological Indices in Contrast-Induced Nephropathy Among Patients Receiving Coronary Intervention: A Systematic Review and Meta-Analysis.2021Angiology
  31. Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention.2021BMC nephrology免费全文
  32. Standard vs. double dose of intravenous nicorandil in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing elective coronary procedures.2021Coronary artery diseaseRCT
  33. Flow reserve fraction: the optimal choice in lesion assessing and interventional guiding for patient with unstable angina pectoris and intermediate lesion wrapped with myocardial bridge: a case report.2021Journal of cardiothoracic surgery免费全文
  34. Clinical outcomes after percutaneous coronary intervention for early versus late and very late stent thrombosis: a systematic review and meta-analysis.2021Journal of thrombosis and thrombolysis免费全文
  35. Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction.2021Lipids in health and disease免费全文
  36. Bivalirudin in patients undergoing percutaneous coronary intervention and independent predictors of postoperative adverse events in these patients: A real world retrospective study.2021Medicine免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)15
  1. TTE Improves Clinical Management of Stable Chest Pain正在招募NCT07063147牵头方2025-01 启动
  2. CCTA Improves Clinical Management of Stable Chest Pain正在招募NCT04691037牵头方2016-01 启动
  3. Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction正在招募NCT07110415研究中心IV期2025-11 启动
  4. Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System即将招募NCT04995159研究中心不分期2021-09 启动
  5. Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus状态不明NCT05649488研究中心不分期2023-02 启动
  6. Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease已完成NCT05509296研究中心不分期2022-09 启动
  7. The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis状态不明NCT04569669研究中心不分期2020-10 启动
  8. Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis已完成NCT04240444研究中心不分期2020-10 启动
  9. Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)已完成NCT04624854研究中心IV期2020-10 启动
  10. Quantitative Flow Ratio (QFR) Guided Coronary Artery Bypass Grafting for Patients Undergoing Primary Valve Surgery With Concomitant Coronary Artery Disease进行中,不再招募NCT03977129研究中心不分期2019-08 启动
  11. Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium已完成NCT03671603研究中心2018-11 启动
  12. Clinical and Genetic Characteristics of Coronary Artery Disease in Chinese Young Adults状态不明NCT02496858研究中心2017-05 启动
  13. Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease已完成NCT01735305研究中心2012-11 启动
  14. A Trial to Evaluate Efficacy of Heart-protecting Musk Pill状态不明NCT01897805研究中心IV期2011-07 启动
  15. Acarbose Cardiovascular Evaluation Trial已完成NCT00829660研究中心IV期2009-02 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性心脏病

Congenital heart disease

2021–2025 年中国大陆作者发表的 2,604 篇先天性心脏病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 1120242025: 112025

天津有 6 家医院列在先天性心脏病下全国有 207 家医院列在先天性心脏病下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的先天性心脏病开放试验。

这些数字背后的记录
论文中的科室病理/检验科

医院名称从作者地址自动识别,尚未人工核对。

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 1120242025: 002025

天津有 10 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    发布
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、运城、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

医院名称从作者地址自动识别,尚未人工核对。

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

天津有 2 家医院列在法布雷病下全国有 80 家医院列在法布雷病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    分期
    未注明
    开始
    2025-11
    发布
    登记号
    NCT07187440

    年龄 7 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心北京、南京、合肥、哈尔滨、天津、太原、成都、杭州、汕头、深圳、石家庄、福州、苏州、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

医院名称从作者地址自动识别,尚未人工核对。

牵头的论文1
  1. Vericiguat improves cardiac function and microcirculation of a male patient with Fabry disease: A case report.2024Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease正在招募NCT07187440研究中心2025-11 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

天津市胸科医院

Tianjin Chest Hospital

天津

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
TJCH

提出更正下载数据